Related Experiment Video
Updated: Nov 28, 2025
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
18.4K
Altered Biodistribution of 68Ga-DOTATOC
Anne-Claire Dupont1, Fanny Borrelly2, Thierry Lecomte3
1From the Departments of Nuclear Pharmacy.
Clinical Nuclear Medicine
|November 25, 2020
Summary
Gallium-68 DOTATOC PET/CT scans showed unusual tracer distribution in a neuroendocrine tumor patient. High turmeric intake may interfere with tracer uptake by affecting liver processes.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmacology
Background:
- Neuroendocrine tumors (NETs) are often diagnosed and monitored using somatostatin receptor imaging.
- Gallium-68 DOTATOC (68Ga-DOTATOC) Positron Emission Tomography/Computed Tomography (PET/CT) is a key imaging modality for NETs.
- Somatostatin analogs are crucial for both treatment and imaging in NET patients.
Observation:
- A patient with metastatic neuroendocrine tumor presented with atypical 68Ga-DOTATOC biodistribution during PET/CT.
- The scan revealed increased vascular uptake and significantly reduced tracer fixation on known metastatic lesions.
- This occurred despite a temporary pause in the patient's somatostatin analog therapy.
Findings:
- The abnormal biodistribution suggests a potential interference with the standard imaging protocol.
- A hypothesis was formed implicating high dietary intake of turmeric as a possible factor.
- Turmeric may inhibit hepatic uptake mechanisms, thereby altering 68Ga-DOTATOC distribution.
Implications:
- This case highlights a potential drug-food interaction affecting diagnostic accuracy in neuroendocrine tumor imaging.
- Clinicians should consider dietary factors, such as turmeric consumption, when interpreting 68Ga-DOTATOC PET/CT scans.
- Further research is warranted to elucidate the interaction between turmeric and somatostatin receptor imaging in NET patients.
